Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up-Reference-Cited by-同舟云学术

Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up

Published:2022-04-13 Issue:5 Volume:6 Page:e712
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:

Author:

Dreyling Martin,Goy Andre,Hess Georg,Kahl Brad S.,Hernández-Rivas José-Ángel,Schuier Natasha,Qi Keqin,Deshpande Sanjay,Zhu Angeline,Parisi Lori,Wang Michael L.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hematology

Reference11 articles.

1. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse.;Kumar;Blood Cancer J,2019

2. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.;Dreyling;Ann Oncol,2017

3. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.;Dreyling;Lancet,2016

4. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.;Wang;N Engl J Med,2013

5. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis.;Rule;Haematologica,2019

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dismantling relapsed/refractory mantle cell lymphoma;Blood Reviews;2024-09

2. Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study;Blood;2024-08-29

3. BTKi is better: a lesson learned?;Blood;2024-08-29

4. SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024;Clinical Lymphoma Myeloma and Leukemia;2024-08

5. Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma;BLOOD ADV;2024